UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): December 7, 2005
ADVENTRX Pharmaceuticals, Inc.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation)
| |
|
|
001-32157
(Commission File Number)
|
|
84-1318182
(IRS Employer Identification No.) |
6725 Mesa Ridge Road, Suite 100
San Diego, California 92121
(Address of principal executive offices) (Zip Code)
(858) 552-0866
(Company’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the registrant under any of the following provisions:
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
TABLE OF CONTENTS
Item 8.01. Other Events.
On December 7, 2005, the Company announced that it had conducted a pre-IND meeting with the
US Food and Drug Administration regarding a proposed 505(b)(2) New Drug Application regulatory plan
for ANX-530 (vinorelbine emulsion) and that the FDA has affirmed the Company’s proposal to conduct
a single bioequivalency study of ANX-530 as a marketing-enabling clinical trial.
The press release issued by the Company on December 7, 2005 with respect to this matter is
included with this report as an exhibit.
Item 9.01. Financial Statements and Exhibits.
| |
|
|
(99)
|
|
(c) The exhibit list required by this item is incorporated by reference to the Exhibit Index
filed as part of this report. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
|
|
|
|
| |
ADVENTRX Pharmaceuticals, Inc.
|
|
| |
By: |
/s/ Carrie E. Carlander
|
|
| |
|
Name: |
Carrie E. Carlander |
|
| |
|
Title: |
Chief Financial Officer, Vice
President |
|
| |
|
Finance, and Treasurer |
|
| |
| |
|
|
December 7, 2005 |
|